360bigviktor, 360chinad, 360conficker, 360cryptolocker, 360gameover, 360locky, 360necurs, 360suppobox, 360tofsee, 360virut, abuseipdb, alienvault, atmos, badips ...
BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Earnings call OpenText delivered Q2 FY26 revenue of $1.33B, exceeding internal expectations, with 3.4% YoY cloud revenue growth and 18% growth in enterprise cloud bookings. Management reaffirmed FY26 ...
SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49 th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on ...
BEDFORD, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results